In the phase 3 trial, Leqembi was shown to slow cognitive decline in early Alzheimer’s patients - measured using the Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale at 18 months of ...
Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease ... Clinical Dementia Rating Sum of Boxes (CDR-SB). In the Clarity AD clinical ...
According to Eisai, the delay by the EMA has been made for procedural reasons, rather than any issues with the regulatory package for Leqembi (lecanemab), which has been approved in the US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback